Fintepla(fenfluramine)
Fintepla (fenfluramine) is a small molecule pharmaceutical. Fenfluramine was first approved as Fintepla on 2020-06-25. It is used to treat autistic disorder, bulimia, and obesity in the USA. It has been approved in Europe to treat myoclonic epilepsies. It is known to target tryptophan 5-hydroxylase 2 and tryptophan 5-hydroxylase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Fintepla
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fintepla | New Drug Application | 2025-04-14 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| obesity | EFO_0001073 | D009765 | E66.9 |
| bulimia | — | D002032 | F50.2 |
| autistic disorder | EFO_0003758 | D001321 | F84.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
FENFLURAMINE HYDROCHLORIDE, FINTEPLA, UCB INC | |||
| 2029-09-25 | PED | ||
| 2029-03-25 | ODE-393 | ||
| 2027-12-25 | PED | ||
| 2027-06-25 | ODE-312 | ||
| 2025-09-25 | PED | ||
| 2025-03-25 | I-887 | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Fenfluramine Hydrochloride, Fintepla, Ucb Inc | |||
| 10452815 | 2038-06-29 | U-2859 | |
| 10603290 | 2037-08-02 | U-2861, U-3347 | |
| 11040018 | 2037-08-02 | U-2861, U-3347 | |
| 11406606 | 2037-08-02 | U-3406, U-3407 | |
| 11759440 | 2037-08-02 | U-3694 | |
| 11786487 | 2037-08-02 | U-3733 | |
| 10947183 | 2036-12-20 | DS, DP | |
| 9549909 | 2033-05-03 | U-2858 | |
| 9603814 | 2033-05-03 | U-2858 | |
| 9603815 | 2033-05-03 | U-2858 | |
| 9610260 | 2033-05-03 | U-2858 | |
| 10478441 | 2033-05-03 | U-2860 | |
| 10478442 | 2033-05-03 | U-2860 | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A08: Antiobesity preparations, excl. diet products
— A08A: Antiobesity preparations, excl. diet products
— A08AA: Centrally acting antiobesity products
— A08AA02: Fenfluramine
N: Nervous system drugs
— N03: Antiepileptics
— N03A: Antiepileptics
— N03AX: Other antiepileptics in atc
— N03AX26: Fenfluramine
HCPCS
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myoclonic epilepsies | D004831 | EFO_1001900 | G40.4 | — | — | 1 | 1 | — | 2 |
| Syndrome | D013577 | — | — | — | — | 1 | 1 | — | 2 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fenfluramine |
| INN | fenfluramine |
| Description | Fenfluramine is a secondary amino compound that is 1-phenyl-propan-2-amine in which one of the meta-hydrogens is substituted by trifluoromethyl, and one of the hydrogens attached to the nitrogen is substituted by an ethyl group. It binds to the serotonin reuptake pump, causing inhbition of serotonin uptake and release of serotonin. The resulting increased levels of serotonin lead to greater serotonin receptor activation which in turn lead to enhancement of serotoninergic transmission in the centres of feeding behavior located in the hypothalamus. This suppresses the appetite for carbohydrates. Fenfluramine was used as the hydrochloride for treatment of diabetes and obesity. It was withdrawn worldwide after reports of heart valve disease and pulmonary hypertension. It has a role as a serotonin uptake inhibitor, a serotonergic agonist and an appetite depressant. It is a secondary amino compound and a member of (trifluoromethyl)benzenes. |
| Classification | Small molecule |
| Drug class | Serotonin–norepinephrine releasing agent; Serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor agonist; Anoretic; Anticonvulsant |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCNC(C)Cc1cccc(C(F)(F)F)c1 |
Identifiers
| PDB | — |
| CAS-ID | 458-24-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL87493 |
| ChEBI ID | 5000 |
| PubChem CID | 3337 |
| DrugBank | DB00574 |
| UNII ID | 2DS058H2CF (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Fintepla – Zogenix
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Fenfluramine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,722 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fintepla
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,552 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use